Cardiac Surgery Cardioprotection
Cardiac surgery patients face significant risks of myocardial ischemia-reperfusion injury, leading to post-operative complications, extended ICU stays, and increased mortality. Current cardioprotective strategies remain inadequate.
NAB-DR01 is a natural-sourced cardioprotective agent formulated using our proprietary mucosal adsorption platform. It targets key pathways involved in ischemia-reperfusion injury, offering pre-operative prophylaxis with improved bioavailability and reduced systemic side effects.
The compound activates endogenous cardioprotective signaling cascades, including the RISK and SAFE pathways, while simultaneously reducing oxidative stress and inflammatory mediator release during reperfusion.
